Trailhead Biosystems appoints Joshua Snow as CCO in Cleveland

On September 16, 2024, Trailhead Biosystems, a biotechnology firm based in Cleveland, announced the appointment of Joshua Snow as Chief Commercial Officer. Dr. Snow brings over 20 years of experience in biotechnology, having previously served as Executive Director of Therapeutics Commercial Operations at Fujifilm Cellular Dynamics. His role involved overseeing commercial partnerships and growth strategies in the stem cell therapy sector. Before his tenure at Fujifilm, Dr. Snow was Director of Business Development and Marketing Strategy at Mirus Bio, where he played a crucial role in launching products for the GMP viral vector manufacturing market. His efforts contributed to Mirus's acquisition by Gamma Biosciences in 2021, showcasing his capability in driving business growth and strategic initiatives. Dr. Snow holds a PhD in Cellular and Molecular Biology from the University of Wisconsin-Madison, which complements his extensive background in biotechnology and cell biology. His appointment comes as Trailhead is poised to enter the commercial market with multiple cell products, indicating a significant growth phase for the company. Jan Jensen, CEO and founder of Trailhead, expressed confidence in Dr. Snow's ability to build a robust commercial infrastructure. Dr. Snow himself highlighted the opportunity to work with a visionary team focused on advancing iPSC-based cell therapy and drug discovery, aiming to make a meaningful impact on patient lives through innovative products.